OP29
p53（Ab-3）（突变型）小鼠单克隆抗体（PAb240）
liquid, clone PAb240, Calbiochem®
别名:
突变型p53抗体
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.41
UNSPSC Code:
12352203
Clone:
PAb240, monoclonal
Species reactivity:
mouse, rat, human, chicken, hamster, bovine
Application:
—
Citations:
19
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
PAb240, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
mouse, rat, human, chicken, hamster, bovine
should not react with
Xenopus
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Flow Cytometry (1-20 µg/mL)
Frozen Sections (10 µg/mL)
Gel Shift
Immunoblotting (5 µg/mL)
Immunofluorescence (1-20 µg/mL,
Immunoprecipitation (1 µg per sample)
Paraffin Sections )
isotype
IgG1
shipped in
wet ice
Quality Level
Gene Information
human ... TP53(7157)
target post-translational modification
unmodified
正在寻找类似产品? 访问 产品对比指南
General description
在非变性条件下，通过免疫沉淀、免疫荧光和流式细胞术识别~53 kDa突变型p53蛋白。在变性条件下通过免疫印迹和石蜡切片识别突变型和野生型p53。
该抗p53（Ab-3）（突变体）小鼠mAb（PAb240）经验证可用于FC、冰冻切片、凝胶阻滞、免疫印迹、IF、IP和石蜡切片，以检测p53（Ab-3）（突变体）。
通过用指定的免疫原免疫BALB/c小鼠并将脾细胞与SP2小鼠骨髓瘤细胞融合而产生的纯化小鼠单克隆抗体（请参阅应用参考）。在非变性条件下，识别~53 kDa突变型p53蛋白。在变性条件下识别突变型和野生型p53蛋白。
Immunogen
人
由p53的氨基酸14-389与β-半乳糖苷酶融合而成的重组蛋白
表位：氨基酸213-217内
Application
流式细胞仪（1-20 µg/ml）
冷冻切片（10 µg/ml）
凝胶阻滞（请参阅备注）
免疫印迹（5 µg/ml）
免疫荧光（1-20 µg/ml，请参阅应用参考）
免疫沉淀（每个样品1 µg）
石蜡部分（请参阅应用参考）
冷冻切片（10 µg/ml）
凝胶阻滞（请参阅备注）
免疫印迹（5 µg/ml）
免疫荧光（1-20 µg/ml，请参阅应用参考）
免疫沉淀（每个样品1 µg）
石蜡部分（请参阅应用参考）
Packaging
请参考特定浓度批号的标签。
Physical form
溶于50 mM磷酸钠缓冲液（pH 7.5），含0.2％明胶。
Analysis Note
阳性对照
A431、Hs27（野生型p53）或SK-BR-3细胞或乳腺癌组织
A431、Hs27（野生型p53）或SK-BR-3细胞或乳腺癌组织
阴性对照
SK-OV-3细胞
SK-OV-3细胞
Other Notes
El-Deiry, W.S., et al. 1994.Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994.Cancer Res.54, 4855.
Barak, Y., et al. 1993.EMBO J.12, 461.
Kastan, M.B., et al. 1992.Cell71, 587.
Kuerbitz, S.J.1992.Proc.Natl.Acad.Sci. USA89, 7491.
Lane, D.P.1992.Nature358, 15.
Kastan, M.B., et al. 1991.Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994.Cancer Res.54, 4855.
Barak, Y., et al. 1993.EMBO J.12, 461.
Kastan, M.B., et al. 1992.Cell71, 587.
Kuerbitz, S.J.1992.Proc.Natl.Acad.Sci. USA89, 7491.
Lane, D.P.1992.Nature358, 15.
Kastan, M.B., et al. 1991.Cancer Res.51, 6304.
在非变性条件下（免疫沉淀、免疫荧光和冰冻切片），抗p53（Ab-3）不识别正常（野生型）p53蛋白；它识别通过激活突变或变性暴露的表位。在变性方案（免疫印迹和石蜡切片）中，抗p53（Ab-3）将识别突变型和野生型p53。不会识别某些具有RHSVV表位突变的p53分子，但会与具有RHSVV表位的TFIIIA反应。对于凝胶阻滞分析，使用目录编号OP29L，复溶于100 µl缓冲液中。在单个系统中，应对抗体进行滴定以获得最佳结果。
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
毒性：标准处理（A）
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Preethi H Gunaratne et al.
Cancer, 125(14), 2409-2422 (2019-04-24)
Over 96% of high-grade ovarian carcinomas and 50% of all cancers are characterized by alterations in the p53 gene. Therapeutic strategies to restore and/or reactivate the p53 pathway have been challenging. By contrast, p63, which shares many of the downstream
Tae Won Kwak et al.
OncoTargets and therapy, 10, 137-144 (2017-01-06)
Epigallocatechin-3-gallate (EGCG) is an antioxidant agent derived from green tea. Because it has chemopreventive and anti-invasive effect against various cancer cells, EGCG can be used to inhibit proliferation and invasion of cholangiocarcinoma (CCA) cells. The anticancer effects of EGCG were
Zih-Yin Lai et al.
International journal of molecular sciences, 22(16) (2021-08-28)
As the most common gene mutation found in cancers, p53 mutations are detected in up to 96% of high-grade serous ovarian carcinoma (HGSOC). Meanwhile, mutant p53 overexpression is known to drive oncogenic phenotypes in cancer patients and to sustain the
Elisa Borrás et al.
European journal of biochemistry, 270(7), 1493-1501 (2003-03-26)
Several clinical trials have revealed that individuals who were given beta-carotene and vitamin A did not have a reduced risk of cancer compared to those given placebo; rather, vitamin A could actually have caused an adverse effect in the lungs
Eva-Maria Fabricius et al.
International journal of oncology, 39(5), 1083-1097 (2011-07-26)
The prognosis for patients with head and neck tumors (HNSCC) is poor, due among other things to the high-risk factor for locoregional recurrence and/or second primary tumors. Extensive studies on chemoprevention of oral pre-cancers to stop carcinogenesis and to prevent
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持